Compare Redwire Corporation (RDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Redwire Corporation trades at $9.57 (market cap $2.44B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 52.3× Redwire Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RDW | VRTX | |
|---|---|---|
Market Cap | $2.44B | $127.55B |
Volume | 11,053,212 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $25.90 | $557.96 |
52-Week Low | $5.06 | $407.37 |
Typical Hold Time | 18 Days | 120 Days |
Enterprise Value | $1.97B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $9.57, down 6.54% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, though revenue growth remains strong at 89.6% year-over-year. Recent developments include a $980 million Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data center technology.
Despite strong analyst support (80% buy ratings) and a $14.88 price target suggesting 55% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents high-risk speculation on space infrastructure growth, dependent on successful execution and SpaceX's Starship development timeline.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
